{"name":"NFlection Therapeutics, Inc.","slug":"nflection-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxQWkJqN081SHFkRnh5ajBfWExOQl9Ka0RKWjVrOU5KOHEzRm1iNUJhZEx0bm1XNThHbFVLbGJuR240RHhuODZDM3pRWFZsUjd0YmstVEhBRDAzWlF4WDdqMnducGx6ZG5ubHJvUTNBa3hYc2x3REtrUkFHdGl4alJ5OVZlbFRsRmxqdGNkeTNFYzRBNVlqZFd1T0ZKZ2dHdExyZzJRb253MmFMcjZlcElYOTRfWVBheERsaGtuZW16VjVPTnVmdFdjYWNnWENhMFlfdll0QzJYM3pMREtScklyd2JlbkZ1U1QwMUpSc2k1clIyM2Y2N3ZrNVZxSUI4ZnNRRWoxZkZqczEtQmZCcTVMWEs1c0RhWG51N0RrYW1jVWNMNEY4MUZiNHFQY1NtVWo0eUZPNFYyT1ZITzZv?oc=5","date":"2025-05-15","type":"pipeline","source":"GlobeNewswire","summary":"Neurofibromatosis Type 1 Market Set to Witness Significant - GlobeNewswire","headline":"Neurofibromatosis Type 1 Market Set to Witness Significant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNQkRDUE9hQjd1MUVkNGEtY2NwYU54S1hBak1uaHpGWWdDNDZBeXJKVEVxQUtCVjlpdzJTcW9uajlSM1dTQjAyOXo1RVpkdUgtOGRKaEFHY3h1QWlYcDhhVHo0Q2VmdVlBaDZoeDFoNU5keFR6M1N6bE92MTBKMXgzLURIN3FIVFBaNGk0a2czSndhWjU5dzQwQmhCOHc?oc=5","date":"2025-05-09","type":"pipeline","source":"openPR.com","summary":"Neurofibrosarcoma Pipeline Appears Robust With 15+ Key Pharma - openPR.com","headline":"Neurofibrosarcoma Pipeline Appears Robust With 15+ Key Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQejdTQk1jNm16RGRJMjB2T05BSndMX3RiUWktblFhclFrRUV4aGcyeFluX09PZi1kVzRvLVEyZEFIaVgxTFpTanBsbDJnVmVING1kdFBNWXhIeHcwQ1BUTXRoMUdSY1dhUlVUODZCSkpISnFGT296QmxDSjFGcmdoTFJQaW1uRTZTMFpxeUhCdWFFaHBtUGw0T1hocGpKUHFvaHBsbGNLR3RKVmJKRlE4VGcwQ2FfUXlrOVZvY3FaOTQwSmF5akZ1U3haSlU4Q1BudHk0dWJZRmVEUngtZHRvWWREUG9xTlQzQTBfdjJhaVJmMGFWbkdwcXM3Q1FuUmptWEZueTdB?oc=5","date":"2025-02-06","type":"pipeline","source":"BioSpace","summary":"Neurofibroma Market Expected to Exhibit a CAGR of 11.5% During 2025-2035, Impelled by Advances in Genetic Research and Precision Medicine - BioSpace","headline":"Neurofibroma Market Expected to Exhibit a CAGR of 11.5% During 2025-2035, Impelled by Advances in Genetic Research and P","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNdUhMNWZsbUNmb20ybE52aFg5UkFVZGw3SHcxUFNpc0hPY0dNcWRveGo5alpjaG1oWlZCVi03Vm5ESElwWmdSb2M3VElXTXFabmxucGVGRF9xVTgtOU5IZ3duSlh2WEpPUEVIN0ptZ2xLUmtvYXd3ZThuYjdKWjhYYW5xOVdMamx5Y1RpY1AxcHRHRzhuX1h0VTJJVy02NGR0bWRwWWkxNFNmbmlSaDZGaWo2c2daeTZMM3JCVDlxcU9DVUU?oc=5","date":"2025-01-10","type":"pipeline","source":"RTTNews","summary":"Atai Life Sciences Appoints Gerd Kochendoerfer As COO; Srinivas Rao Assumes Sole CEO Role - RTTNews","headline":"Atai Life Sciences Appoints Gerd Kochendoerfer As COO; Srinivas Rao Assumes Sole CEO Role","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wJBVV95cUxQX0w5RXFoWWtjbjFHblg3ZGxFNW5YSFVPcXlNVnhyQ2N5T3U4YnphNE1JamRvUzREZjJWcTNkRWUtbWVtYWN1X25rdzBZa3AtSzl4WWtVTE1MUUZTZWdtVk1GVUc1UEJiYldabmg2ZXRzM3ZmUm9aTFM5b1VHNVlUZUdYM1BXY3g2TTNTbUlRLW04eXV2S2EtR3JRMTFtOURmeXhuaXU3N3ZieFhvdk1jYVFPb2tjSmJSd0FjUmk0blpOT0haVVZzZUhKNmNYSUFTMHR3Q0VKVkNJclRmYUNBWGxJX2Z2QmJYTDFVSDg1YUtYdHM4YTAwbDN6TjkzRnZ5cTY4RDd3NGVDVWhEcnJ2MG1fV3FLOWFyUkdodGo0Q0NmNVpSSW9OdHpuOHRqUG1XbVFqRmVkcC1fWkVaVXZmSF9PSVVjWnV4WmVrTWJsSjNmb0hxTDFZ?oc=5","date":"2023-11-14","type":"pipeline","source":"PR Newswire","summary":"Neurofibromatosis Type 2 Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - Novartis, AstraZeneca, GlaxoSmithKline, Ikena, SpringWorks, Vivace, Recursion - PR Newswi","headline":"Neurofibromatosis Type 2 Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - Novartis,","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2021-05-26","type":"trial","source":"PR Newswire","summary":"NFlection Therapeutics' NFX-179 Gel Demonstrates Safety and Significant Reduction in p-ERK, a Key Biomarker Driving Neurofibroma Tumor Growth, in Positive Data From a 28-Day Phase 2a Clinical Trial - ","headline":"NFlection Therapeutics' NFX-179 Gel Demonstrates Safety and Significant Reduction in p-ERK, a Key Biomarker Driving Neur","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxOY21rLXZBby1SRHZqVW9MYWU5Rmd6QUwzRkdiRDZnN0dIengwZlRMTDJ3azBQczlyc2NSaHBzVEppWUF2ZGhuajFwWU5MenJ0Y0hGTVlVOC1XWmV6YzEzMTVJbHRtS1RMN1ZJWmFhSHlIbVA4cnhvSFU0N3dBdGtJME9FSUlRa0dvMGE1Y0lycGl0TVQ4SC1IX3A2RDB4cWZ4SzNfUVFRTGdXVnNnODBFQnVqZm5GSmRuank5ZzQ1ZlZFWmRiM3o3aldLVXhHb2U2R1pOS2d6QWRrLXJQVW02X2VJRXdNTGlCaUlqNURTQQ?oc=5","date":"2020-06-09","type":"pipeline","source":"PR Newswire","summary":"NFlection Therapeutics Launches with $20M Series A Funding to Advance Lead Program in Neurofibromatosis - PR Newswire","headline":"NFlection Therapeutics Launches with $20M Series A Funding to Advance Lead Program in Neurofibromatosis","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}